title: [Animal models for bone and joint disease. RANKL-injected bone loss model].
abstract: Discovery of the osteoclast differentiation factor RANKL (receptor activator of NF-κB ligand) has opened a new era in the understanding of mechanisms in osteoclast differentiation over the last decade. The discovery results in the development of a fully human anti-RANKL neutralizing monoclonal antibody (called denosumab) and denosumab has been approved for the treatment of osteoporosis in Europe and the US. Here I review a novel rapid bone loss model with GST (glutathione-S-transferase) -RANKL. Pharmacologic studies of candidates for the treatment of osteoporosis with this model can be done in short periods such as 3 days and a couple of weeks although it took several months in the conventional methods with ovariectomized (OVX) -rats. This model also is useful for the rapid analyses in the functions of osteoclasts in vivo . I am expecting the RANKL-induced bone loss model to be the gold standard in the animal osteoporosis model as well as OVX-rats in the near future.
authors.affiliation: Bioindustry Division, Oriental Yeast Company Limited.
authors.forename: Hisataka
authors.initials: H
authors.lastname: Yasuda
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D002454:Cell Differentiation / Q000187:drug effects; D000069448:Denosumab; D004195:Disease Models, Animal; D015195:Drug Design; D005982:Glutathione Transferase / Q000008:administration & dosage / Q000494:pharmacology; D010010:Osteoclasts / Q000166:cytology; D010024:Osteoporosis / Q000188:drug therapy / Q000209:etiology; D053245:RANK Ligand / Q000008:administration & dosage / Q000494:pharmacology; D051381:Rats
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053245:RANK Ligand; D000069448:Denosumab; D005982:Glutathione Transferase